| Year |
Citation |
Score |
| 2023 |
Kado SY, Bein K, Castaneda AR, Pouraryan AA, Garrity N, Ishihara Y, Rossi A, Haarmann-Stemmann T, Sweeney CA, Vogel CFA. Regulation of IDO2 by the Aryl Hydrocarbon Receptor (AhR) in Breast Cancer. Cells. 12. PMID 37408267 DOI: 10.3390/cells12101433 |
0.392 |
|
| 2022 |
Sweeney C, Lazennec G, Vogel CFA. Environmental exposure and the role of AhR in the tumor microenvironment of breast cancer. Frontiers in Pharmacology. 13: 1095289. PMID 36588678 DOI: 10.3389/fphar.2022.1095289 |
0.395 |
|
| 2022 |
Umeh-Garcia M, O'Geen H, Simion C, Gephart MH, Segal DJ, Sweeney CA. Aberrant promoter methylation contributes to LRIG1 silencing in basal/triple-negative breast cancer. British Journal of Cancer. PMID 35440669 DOI: 10.1038/s41416-022-01812-8 |
0.371 |
|
| 2021 |
Vogel CFA, Lazennec G, Kado SY, Dahlem C, He Y, Castaneda A, Ishihara Y, Vogeley C, Rossi A, Haarmann-Stemmann T, Jugan J, Mori H, Borowsky AD, La Merrill MA, Sweeney C. Targeting the Aryl Hydrocarbon Receptor Signaling Pathway in Breast Cancer Development. Frontiers in Immunology. 12: 625346. PMID 33763068 DOI: 10.3389/fimmu.2021.625346 |
0.489 |
|
| 2020 |
Candas-Green D, Xie B, Huang J, Fan M, Wang A, Menaa C, Zhang Y, Zhang L, Jing D, Azghadi S, Zhou W, Liu L, Jiang N, Li T, Gao T, ... Sweeney C, et al. Dual blockade of CD47 and HER2 eliminates radioresistant breast cancer cells. Nature Communications. 11: 4591. PMID 32929084 DOI: 10.1038/S41467-020-18245-7 |
0.46 |
|
| 2020 |
Sweeney C. Targeting the polyamine pathway-"a means" to overcome chemoresistance in triple-negative breast cancer. The Journal of Biological Chemistry. 295: 6278-6279. PMID 32385094 DOI: 10.1074/Jbc.H120.013736 |
0.468 |
|
| 2019 |
Umeh-Garcia M, Simion C, Ho PY, Batra N, Berg AL, Carraway KL, Yu A, Sweeney C. A Novel Bioengineered MicroRNA-127 Prodrug Suppresses The Growth And Metastatic Potential Of Triple Negative Breast Cancer Cells. Cancer Research. PMID 31694904 DOI: 10.1158/0008-5472.Can-19-0656 |
0.382 |
|
| 2019 |
Vogel CFA, Ishihara Y, Campbell CE, Kado SY, Nguyen-Chi A, Sweeney C, Pollet M, Haarmann-Stemmann T, Tuscano JM. A Protective Role of Aryl Hydrocarbon Receptor Repressor in Inflammation and Tumor Growth. Cancers. 11. PMID 31035533 DOI: 10.3390/Cancers11050589 |
0.54 |
|
| 2018 |
Rowson-Hodel AR, Wald JH, Hatakeyama J, O'Neal WK, Stonebraker JR, VanderVorst K, Saldana MJ, Borowsky AD, Sweeney C, Carraway KL. Membrane Mucin Muc4 promotes blood cell association with tumor cells and mediates efficient metastasis in a mouse model of breast cancer. Oncogene. 37: 197-207. PMID 28892049 DOI: 10.1038/Onc.2017.327 |
0.432 |
|
| 2017 |
Wald JH, Hatakeyama J, Printsev I, Cuevas A, Fry WHD, Saldana MJ, VanderVorst K, Rowson-Hodel A, Angelastro JM, Sweeney C, Carraway KL. Suppression of planar cell polarity signaling and migration in glioblastoma by Nrdp1-mediated Dvl polyubiquitination. Oncogene. 36: 5158-5167. PMID 28481871 DOI: 10.1038/Onc.2017.126 |
0.499 |
|
| 2017 |
Candas D, Zhang L, Menaa C, Fan M, Zhang Y, Liu L, Zhou W, Azghadi S, Sweeney C, Shen R, Lin T, Pan C, Vaughan AT, Wang JM, Chen H, et al. Abstract LB-226: Dual inhibition of CD47 and HER2 to radiosensitize breast cancer cells Cancer Research. 77. DOI: 10.1158/1538-7445.Am2017-Lb-226 |
0.429 |
|
| 2016 |
Hatakeyama J, Wald JH, Rafidi H, Cuevas A, Sweeney C, Carraway KL. The ER structural protein Rtn4A stabilizes and enhances signaling through the receptor tyrosine kinase ErbB3. Science Signaling. 9: ra65. PMID 27353365 DOI: 10.1126/Scisignal.Aaf1604 |
0.79 |
|
| 2016 |
Amir S, Simion C, Umeh-Garcia M, Krig S, Moss T, Carraway KL, Sweeney C. Regulation of the T-box transcription factor Tbx3 by the tumour suppressor microRNA-206 in breast cancer. British Journal of Cancer. PMID 27100732 DOI: 10.1038/Bjc.2016.73 |
0.327 |
|
| 2016 |
Rowson-Hodel AR, Berg AL, Wald JH, Hatakeyama J, VanderVorst K, Curiel DA, Leon LJ, Sweeney C, Carraway KL. Hexamethylene amiloride engages a novel reactive oxygen species- and lysosome-dependent programmed necrotic mechanism to selectively target breast cancer cells. Cancer Letters. PMID 26944316 DOI: 10.1016/J.Canlet.2016.02.042 |
0.372 |
|
| 2016 |
Morrison MM, Williams MM, Vaught DB, Hicks D, Lim J, McKernan C, Aurisicchio L, Ciliberto G, Simion C, Sweeney C, Cook RS. Decreased LRIG1 in fulvestrant-treated luminal breast cancer cells permits ErbB3 upregulation and increased growth. Oncogene. 35: 1206. PMID 26935538 DOI: 10.1038/Onc.2015.418 |
0.455 |
|
| 2016 |
Yokdang N, Hatakeyama J, Wald J, Simion C, Tellez J, Chang D, Swamynathan M, Chen M, Murphy W, Carraway K, Sweeney C. Abstract LB-021: LRIG1 opposes epithelial-to-mesenchymal transition and inhibits invasion of triple-negative/basal-B breast cancer cells Cancer Research. 76. DOI: 10.1158/1538-7445.Am2016-Lb-021 |
0.534 |
|
| 2015 |
Yokdang N, Hatakeyama J, Wald JH, Simion C, Tellez JD, Chang DZ, Swamynathan MM, Chen M, Murphy WJ, Carraway Iii KL, Sweeney C. LRIG1 opposes epithelial-to-mesenchymal transition and inhibits invasion of basal-like breast cancer cells. Oncogene. PMID 26387542 DOI: 10.1038/Onc.2015.345 |
0.553 |
|
| 2015 |
Morrison MM, Williams MM, Vaught DB, Hicks D, Lim J, McKernan C, Aurisicchio L, Cennaro G, Simion C, Sweeney C, Cook RS. Decreased LRIG1 in fulvestrant-treated luminal breast cancer cells permits ErbB3 upregulation and increased growth. Oncogene. PMID 26148232 DOI: 10.1038/onc.2015.169 |
0.499 |
|
| 2015 |
Bekki K, Vogel H, Li W, Ito T, Sweeney C, Haarmann-Stemmann T, Matsumura F, Vogel CF. The aryl hydrocarbon receptor (AhR) mediates resistance to apoptosis induced in breast cancer cells. Pesticide Biochemistry and Physiology. 120: 5-13. PMID 25987214 DOI: 10.1016/J.Pestbp.2014.12.021 |
0.411 |
|
| 2015 |
Simion C, Chen QJ, Wilkerson CL, Rafidi H, Borowsky AD, Sweeney C. Abstract 32: The role of Lrig1 signaling in mammary gland development and tumorigenesis Cancer Research. 75: 32-32. DOI: 10.1158/1538-7445.Am2015-32 |
0.77 |
|
| 2014 |
Candas D, Lu CL, Fan M, Chuang FY, Sweeney C, Borowsky AD, Li JJ. Mitochondrial MKP1 is a target for therapy-resistant HER2-positive breast cancer cells. Cancer Research. 74: 7498-509. PMID 25377473 DOI: 10.1158/0008-5472.Can-14-0844 |
0.501 |
|
| 2014 |
Simion C, Cedano-Prieto ME, Sweeney C. The LRIG family: enigmatic regulators of growth factor receptor signaling. Endocrine-Related Cancer. 21: R431-43. PMID 25183430 DOI: 10.1530/ERC-14-0179 |
0.513 |
|
| 2014 |
Frietze S, O'Geen H, Littlepage LE, Simion C, Sweeney CA, Farnham PJ, Krig SR. Global analysis of ZNF217 chromatin occupancy in the breast cancer cell genome reveals an association with ERalpha. Bmc Genomics. 15: 520. PMID 24962896 DOI: 10.1186/1471-2164-15-520 |
0.353 |
|
| 2014 |
Printsev I, Yen L, Sweeney C, Carraway KL. Oligomerization of the Nrdp1 E3 ubiquitin ligase is necessary for efficient autoubiquitination but not ErbB3 ubiquitination. The Journal of Biological Chemistry. 289: 8570-8. PMID 24519943 DOI: 10.1074/Jbc.M113.527036 |
0.489 |
|
| 2014 |
Yokdang N, Sweeney C. Abstract 588: Lrig1 suppresses breast cancer stem cell expansion and promotes mesenchymal to epithelial transition Cancer Research. 74: 588-588. DOI: 10.1158/1538-7445.Am2014-588 |
0.505 |
|
| 2014 |
Candas D, Lu C, Fan M, Chuang F, Sweeney C, Borowsky A, Li JJ. Abstract 3029: MKP1-mediated survival of HER2 positive breast cancer stem cells Cancer Research. 74: 3029-3029. DOI: 10.1158/1538-7445.Am2014-3029 |
0.531 |
|
| 2013 |
Rafidi H, Mercado F, Astudillo M, Fry WH, Saldana M, Carraway KL, Sweeney C. Leucine-rich repeat and immunoglobulin domain-containing protein-1 (Lrig1) negative regulatory action toward ErbB receptor tyrosine kinases is opposed by leucine-rich repeat and immunoglobulin domain-containing protein 3 (Lrig3). The Journal of Biological Chemistry. 288: 21593-605. PMID 23723069 DOI: 10.1074/Jbc.M113.486050 |
0.781 |
|
| 2013 |
Candas D, Chuang F, Fan M, Shen R, Sweeney C, Borowsky A, Vaughan A, Li JJ. Abstract 74: Mitochondrial MKP1-mediated radioresistance in breast cancer stem cells. Cancer Research. 73: 74-74. DOI: 10.1158/1538-7445.Am2013-74 |
0.519 |
|
| 2013 |
Cedano-Prieto ME, Kotelawala L, Sweeney C. Abstract 3033: Negative regulation of ErbB2 611-CTF by LRIG1. Cancer Research. 73: 3033-3033. DOI: 10.1158/1538-7445.Am2013-3033 |
0.618 |
|
| 2012 |
Littlepage LE, Adler AS, Kouros-Mehr H, Huang G, Chou J, Krig SR, Griffith OL, Korkola JE, Qu K, Lawson DA, Xue Q, Sternlicht MD, Dijkgraaf GJ, Yaswen P, Rugo HS, ... Sweeney CA, et al. The transcription factor ZNF217 is a prognostic biomarker and therapeutic target during breast cancer progression. Cancer Discovery. 2: 638-51. PMID 22728437 DOI: 10.1158/2159-8290.Cd-12-0093 |
0.369 |
|
| 2011 |
Krig SR, Frietze S, Simion C, Miller JK, Fry WHD, Rafidi H, Kotelawala L, Qi L, Griffith OL, Gray JW, Carraway KL, Sweeney C. Lrig1 is an estrogen-regulated growth suppressor and correlates with longer relapse-free survival in ERα-positive breast cancer Molecular Cancer Research. 9: 1406-1417. PMID 21821674 DOI: 10.1158/1541-7786.Mcr-11-0227 |
0.778 |
|
| 2011 |
Vogel CF, Li W, Wu D, Miller JK, Sweeney C, Lazennec G, Fujisawa Y, Matsumura F. Interaction of aryl hydrocarbon receptor and NF-κB subunit RelB in breast cancer is associated with interleukin-8 overexpression. Archives of Biochemistry and Biophysics. 512: 78-86. PMID 21640702 DOI: 10.1016/J.Abb.2011.05.011 |
0.398 |
|
| 2011 |
Fry WH, Simion C, Sweeney C, Carraway KL. Quantity control of the ErbB3 receptor tyrosine kinase at the endoplasmic reticulum. Molecular and Cellular Biology. 31: 3009-18. PMID 21576364 DOI: 10.1128/Mcb.05105-11 |
0.499 |
|
| 2011 |
Holmlund C, Karlsson T, Borota OC, Miller J, Baofeng W, Zahed F, Sweeney C, Henriksson R, Hedman H. Abstract 1133: LRIG2 promotes PDGF induced experimental glioma Cancer Research. 71: 1133-1133. DOI: 10.1158/1538-7445.Am2011-1133 |
0.579 |
|
| 2010 |
Krig SR, Miller JK, Frietze S, Beckett LA, Neve RM, Farnham PJ, Yaswen PI, Sweeney CA. ZNF217, a candidate breast cancer oncogene amplified at 20q13, regulates expression of the ErbB3 receptor tyrosine kinase in breast cancer cells. Oncogene. 29: 5500-10. PMID 20661224 DOI: 10.1038/Onc.2010.289 |
0.454 |
|
| 2010 |
Ingalla EQ, Miller JK, Wald JH, Workman HC, Kaur RP, Yen L, Fry WH, Borowsky AD, Young LJ, Sweeney C, Carraway KL. Post-transcriptional mechanisms contribute to the suppression of the ErbB3 negative regulator protein Nrdp1 in mammary tumors. The Journal of Biological Chemistry. 285: 28691-7. PMID 20628057 DOI: 10.1074/Jbc.M110.127977 |
0.781 |
|
| 2010 |
Khan IH, Zhao J, Ghosh P, Ziman M, Sweeney C, Kung HJ, Luciw PA. Microbead arrays for the analysis of ErbB receptor tyrosine kinase activation and dimerization in breast cancer cells. Assay and Drug Development Technologies. 8: 27-36. PMID 20035613 DOI: 10.1089/Adt.2009.0208 |
0.415 |
|
| 2010 |
Trainor BC, Crean KK, Fry WH, Sweeney C. Activation of extracellular signal-regulated kinases in social behavior circuits during resident-intruder aggression tests. Neuroscience. 165: 325-36. PMID 19874872 DOI: 10.1016/J.Neuroscience.2009.10.050 |
0.34 |
|
| 2009 |
Workman HC, Miller JK, Ingalla EQ, Kaur RP, Yamamoto DI, Beckett LA, Young LJ, Cardiff RD, Borowsky AD, Carraway KL, Sweeney C, Carraway KL. The membrane mucin MUC4 is elevated in breast tumor lymph node metastases relative to matched primary tumors and confers aggressive properties to breast cancer cells. Breast Cancer Research : Bcr. 11: R70. PMID 19761616 DOI: 10.1186/Bcr2364 |
0.765 |
|
| 2009 |
Workman HC, Sweeney C, Carraway KL. The membrane mucin Muc4 inhibits apoptosis induced by multiple insults via ErbB2-dependent and ErbB2-independent mechanisms. Cancer Research. 69: 2845-52. PMID 19293191 DOI: 10.1158/0008-5472.Can-08-2089 |
0.782 |
|
| 2009 |
Fry WH, Kotelawala L, Sweeney C, Carraway KL. Mechanisms of ErbB receptor negative regulation and relevance in cancer. Experimental Cell Research. 315: 697-706. PMID 18706412 DOI: 10.1016/J.Yexcr.2008.07.022 |
0.447 |
|
| 2008 |
Miller JK, Shattuck DL, Ingalla EQ, Yen L, Borowsky AD, Young LJ, Cardiff RD, Carraway KL, Sweeney C. Suppression of the negative regulator LRIG1 contributes to ErbB2 overexpression in breast cancer. Cancer Research. 68: 8286-94. PMID 18922900 DOI: 10.1158/0008-5472.Can-07-6316 |
0.589 |
|
| 2008 |
Stutz MA, Shattuck DL, Laederich MB, Carraway KL, Sweeney C. LRIG1 negatively regulates the oncogenic EGF receptor mutant EGFRvIII. Oncogene. 27: 5741-52. PMID 18542056 DOI: 10.1038/Onc.2008.185 |
0.483 |
|
| 2008 |
Shattuck DL, Miller JK, Carraway KL, Sweeney C. Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells. Cancer Research. 68: 1471-7. PMID 18316611 DOI: 10.1158/0008-5472.Can-07-5962 |
0.422 |
|
| 2007 |
Carraway KL, Funes M, Workman HC, Sweeney C. Contribution of membrane mucins to tumor progression through modulation of cellular growth signaling pathways. Current Topics in Developmental Biology. 78: 1-22. PMID 17338913 DOI: 10.1016/S0070-2153(06)78001-2 |
0.771 |
|
| 2007 |
Cao Z, Wu X, Yen L, Sweeney C, Carraway KL. Neuregulin-induced ErbB3 downregulation is mediated by a protein stability cascade involving the E3 ubiquitin ligase Nrdp1. Molecular and Cellular Biology. 27: 2180-8. PMID 17210635 DOI: 10.1128/Mcb.01245-06 |
0.431 |
|
| 2007 |
Shattuck DL, Miller JK, Laederich M, Funes M, Petersen H, Carraway KL, Sweeney C. LRIG1 is a novel negative regulator of the Met receptor and opposes Met and Her2 synergy. Molecular and Cellular Biology. 27: 1934-46. PMID 17178829 DOI: 10.1128/Mcb.00757-06 |
0.514 |
|
| 2006 |
Yen L, Cao Z, Wu X, Ingalla ER, Baron C, Young LJ, Gregg JP, Cardiff RD, Borowsky AD, Sweeney C, Carraway KL. Loss of Nrdp1 enhances ErbB2/ErbB3-dependent breast tumor cell growth. Cancer Research. 66: 11279-86. PMID 17145873 DOI: 10.1158/0008-5472.Can-06-2319 |
0.635 |
|
| 2006 |
Carraway KL, Sweeney C. Co-opted integrin signaling in ErbB2-induced mammary tumor progression. Cancer Cell. 10: 93-5. PMID 16904607 DOI: 10.1016/J.Ccr.2006.07.015 |
0.449 |
|
| 2006 |
Sweeney C, Miller JK, Shattuck DL, Carraway KL. ErbB receptor negative regulatory mechanisms: implications in cancer. Journal of Mammary Gland Biology and Neoplasia. 11: 89-99. PMID 16865534 DOI: 10.1007/S10911-006-9015-3 |
0.453 |
|
| 2006 |
Funes M, Miller JK, Lai C, Carraway KL, Sweeney C. The mucin Muc4 potentiates neuregulin signaling by increasing the cell-surface populations of ErbB2 and ErbB3. The Journal of Biological Chemistry. 281: 19310-9. PMID 16690615 DOI: 10.1074/Jbc.M603225200 |
0.53 |
|
| 2004 |
Laederich MB, Funes-Duran M, Yen L, Ingalla E, Wu X, Carraway KL, Sweeney C. The leucine-rich repeat protein LRIG1 is a negative regulator of ErbB family receptor tyrosine kinases. The Journal of Biological Chemistry. 279: 47050-6. PMID 15345710 DOI: 10.1074/Jbc.M409703200 |
0.723 |
|
| 2004 |
Sweeney C, Carraway KL. Negative regulation of ErbB family receptor tyrosine kinases. British Journal of Cancer. 90: 289-93. PMID 14735165 DOI: 10.1038/Sj.Bjc.6601500 |
0.442 |
|
| 2004 |
Wu X, Obata T, Khan Q, Highshaw RA, White RdV, Sweeney C. The phosphatidylinositol‐3 kinase pathway regulates bladder cancer cell invasion Bjui. 93: 143-150. PMID 14678387 DOI: 10.1111/J.1464-410X.2004.04574.X |
0.398 |
|
| 2002 |
Carraway KL, Sweeney C. EGF receptor activation by heterologous mechanisms. Cancer Cell. 1: 405-6. PMID 12124166 DOI: 10.1016/S1535-6108(02)00076-4 |
0.382 |
|
| 2002 |
Ravid T, Sweeney C, Gee P, Carraway KL, Goldkorn T. Epidermal growth factor receptor activation under oxidative stress fails to promote c-Cbl mediated down-regulation. The Journal of Biological Chemistry. 277: 31214-9. PMID 12063263 DOI: 10.1074/Jbc.M204677200 |
0.321 |
|
| 2002 |
Diamonti AJ, Guy PM, Ivanof C, Wong K, Sweeney C, Carraway KL. An RBCC protein implicated in maintenance of steady-state neuregulin receptor levels. Proceedings of the National Academy of Sciences of the United States of America. 99: 2866-71. PMID 11867753 DOI: 10.1073/Pnas.052709799 |
0.482 |
|
| 2001 |
Sweeney C, Fambrough D, Huard C, Diamonti AJ, Lander ES, Cantley LC, Carraway KL. Growth factor-specific signaling pathway stimulation and gene expression mediated by ErbB receptors. The Journal of Biological Chemistry. 276: 22685-98. PMID 11297548 DOI: 10.1074/Jbc.M100602200 |
0.404 |
|
| 2001 |
Carraway KL, Sweeney C. Localization and modulation of ErbB receptor tyrosine kinases. Current Opinion in Cell Biology. 13: 125-30. PMID 11248544 DOI: 10.1016/S0955-0674(00)00188-5 |
0.388 |
|
| 2000 |
Sweeney C, Carraway KL. Ligand discrimination by ErbB receptors: differential signaling through differential phosphorylation site usage. Oncogene. 19: 5568-73. PMID 11114736 DOI: 10.1038/Sj.Onc.1203913 |
0.36 |
|
| 2000 |
Sweeney C, Lai C, Riese DJ, Diamonti AJ, Cantley LC, Carraway KL. Ligand discrimination in signaling through an ErbB4 receptor homodimer. The Journal of Biological Chemistry. 275: 19803-7. PMID 10867024 DOI: 10.1074/Jbc.C901015199 |
0.385 |
|
| Show low-probability matches. |